Hybrid neurological and ophthalmological company eyeBrain Medical raised $6 million in a new round of equity financing for its chronic severe headache treatment technology.
The company is aiming to treat what it calls ‘eyegraines’, or visual misalignments between images from both eyes that eyeBrain says can over stimulate the trigeminal nerve in the brain and trigger persistent headaches, according to the company’s website.
